Skip to content

Clinical application of dopamine transporter and deoxyglucose in chronic migraine

Clinical application of dopamine transporter and deoxyglucose in chronic migraine

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069726
Enrollment
Unknown
Registered
2023-03-24
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine

Interventions

Group of Chronic Migraine:None

Sponsors

Department of Neurology Medicine, The First Medical Centre, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Met the diagnostic criteria for chronic migraine in the International Classification of Headache, Third Edition (ICHD-3). Inclusion criteria included: 1) Headache manifested as more than 15 days per month, lasted for 3 months or more, and had at least 8 headache days per month consistent with the characteristics of migraine; 2); At least 5 headaches that meet the 1.1 B-D criteria for the diagnosis of migraine without aura and/or 1.2 B and C criteria for migraine with aura; 3) The main characteristics are unilateral or bilateral alternating attacks, moderate and severe, throbbing headache and aggravation after fatigue, usually lasting for 4~72h, and may be accompanied by phobias, phobias, nausea, vomiting, etc. Healthy control group included: 1) overall health status; 2) Age and gender matched with patients in the experimental group.

Exclusion criteria

Exclusion criteria: 1) Alcohol addiction or drug dependence; 2) Major mental illness: including anxiety disorder, depression, affective disorder, schizophrenia, or drug-induced psychosis; 3) Neurological diseases, including cerebral infarction, brain tumor, craniocerebral trauma, etc. 4) Patients with serious medical conditions who are currently using respiratory drugs, cardiovascular drugs, anticonvulsants or psychoactive substances; 5) Pregnant and lactating women and those who planned to have a family within 1 month during the experiment; 6) People with severe hearing and visual impairment; 7) Prophylactic administration of migraine drugs before enrollment; 8) Can't cooperate with the interviewer.

Design outcomes

Primary

MeasureTime frame
11C-ß-CFT;18F-FDG;

Countries

China

Contacts

Public ContactRuozhuo Liu

Department of Neurology Medicine, The First Medical Centre, Chinese PLA General Hospital

liurz301@163.com+86 13910880017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026